Blockchain Registration Transaction Record

Onco-Innovations Targets DNA Repair with Novel PNKP Inhibitor

Onco-Innovations advances ONC010, a nanoparticle PNKP inhibitor, in DNA Damage Response market. Preclinical data shows doubled survival in colorectal cancer models. Read more.

This news matters because Onco-Innovations' ONC010 addresses a critical unmet need in cancer treatment: DNA repair mechanisms that tumors exploit to resist therapy. By targeting the PNKP enzyme involved in multiple repair pathways, the drug could overcome resistance to PARP inhibitors and other treatments, offering new hope for patients with PTEN-deficient colorectal cancer and potentially other solid tumors. The company's use of a causal AI platform for development also signals a trend toward more efficient drug discovery, which could accelerate the arrival of effective therapies.